Edward Stelmakh insider trades: OptimizeRx (OPRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Edward reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | OPRX | ↓ Sell | 1,388 | $13.51 | $19K | Direct | Dec 22, 2025 (3d) |
| Aug 15, 2022 | OPRX | ↑ Buy | 3,000 | $15.43 | $46K | Direct | Aug 17, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Edward Stelmakh's insider trades
Edward Stelmakh is Chief Finance & Strat Officer at OptimizeRx (OPRX). Since Aug 15, 2022, Edward has reported 1 open-market purchase worth $46K and 1 sale worth $19K on SEC Form 4. In the last 12 months: 1 sale ($19K).
Their filings also include shares withheld for taxes (10 filings), option exercises (8 filings), grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OPRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.